Treatment of obesity using non-daily administration of 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol
AssigneeZafgen, Inc.
InventorThomas E. Hughes
Life of this patent
Estimating the term…
Abstract
The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions using non-daily administration of e.g, a MetAP-2 inhibitor.
Claims12
A method for treating obesity or for reducing body weight in a human patient having an initial body mass index at least about 30 kg/m2, or at least about 27 kg/m2 and suffering from weight related co-morbidity, and in need thereof, comprising parenterally administering to said patient, once or twice weekly, a dose of a formulation comprising about 0.5 mg/m2 to about 3 mg/m2, based on the patients actual or calculated surface area, of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol or pharmaceutically acceptable salts thereof.
A method for treating obesity or for reducing body weight in a human patient having an initial body mass index at least about 30 kg/m2, or at least about 27 kg/m2 and suffering from weight related co-morbidity, and in need thereof, comprising subcutaneously administering to said patient, once or twice weekly, a dose of a formulation comprising about 0.5 mg/m2 to about 3 mg/m2 of 6-0-(4-dimethylaminoethoxy)cinnamoyl fumagillol or pharmaceutically acceptable salts thereof.
A method for reducing the weight of a human patient having an initial body mass index of at least about 30 kg/m2, or at least about 27 kg/m2 and suffering from weight related co-morbidity, comprising parenterally administering to said patient on a weekly, twice weekly, or every 3 or 4 days basis, a single dose of a parenteral formulation comprising a therapeutically effective amount of a compound 6-O-(4-dimethylaminoethoxy) cinnamoylfumagillol or pharmaceutically acceptable salts thereof.
A method for treating obesity or for reducing body weight in a human patient having an initial body mass index at least about 30 kg/m2, or at least about 27 kg/m2 and suffering from weight related co-morbidity, and in need thereof, comprising parenterally administering to said patient, once or twice weekly, a dose of a formulation comprising about 1.8 mg of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol or pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.